RxDoctor Payments Data

Afrin Farooq, MD

Hospitalist · Milton, MANPI 1407168065

Payments from drug & device makers

$236in general payments, 2019–2025

Across 11 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$58
  • Pfizer$50
  • Novo Nordisk$25
  • Edwards Lifesciences$20
  • AbbVie$18
  • Lilly USA, LLC$17
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$236 in reported general payments places this provider in the 85th percentile of 599 hospitalist providers in Massachusetts.

See all hospitalist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$296,065
Medicare patients
566
Services billed
3,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$212,569
JardianceEmpagliflozin66$81,528
OzempicSemaglutide49$67,493
JanuviaSitagliptin Phosphate55$63,847
MounjaroTirzepatide26$43,745
XareltoRivaroxaban40$35,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$21,704
WegovySemaglutide12$21,406
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$17,031
VascepaIcosapent Ethyl27$15,511
Atorvastatin Calcium723$11,020
Rosuvastatin Calcium260$9,633
Breo ElliptaFluticasone/Vilanterol13$9,145
Metoprolol Succinate391$8,839
Ambien CrZolpidem Tartrate13$7,563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$50$219,277200 claims
Novo NordiskOzempic, Wegovy$25$88,89961 claims
MerckJanuvia$15$63,84755 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$16$47,88164 claims
Lilly USA, LLCMounjaro$17$43,74526 claims
AbbVieSynthroid$18$7,276111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 599 hospitalist providers in Massachusetts.

Other hospitalist in Milton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →